References
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167–78
- Kroner BA, Garnett WR. Pharmacotherapy trials of urinary incontinence in the geriatric patient: a review of current literature findings. J Geriatric Drug Therapy 1992;7(1):23–55
- Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 1990;66(5):479–85
- Tapp AJ, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990;97(6):521–6
- Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991;145(4):813–6
- Burgio KL, Locher JL, Goode PS, et al. Behavioural vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998 December 16;280(23):1995–2000
- Caione P, Arena F, Biraghi M, et al. Nocturnal enuresis and daytime wetting: a multicentric trial with oxybutynin and desmopressin. Eur Urol 1997;31(4):459–63
- Milani R, Scalambrino S, Milia R, et al. Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. Int Urogynecol J 1993;4(1):3–8
- Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999; 161(6):1809–12
- Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10(5):283–9
- Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81(6):801–10
- Harsanyi Z, Darke AC, Krishnamurthy TN. The influence of alginate content in controlled release oxybutynin formulations on Cmax and dissolution rate. In: Proceedings of American Association of Pharmaceutical Scientists, Annual Meeting and Exposition; 2001 October 21–25;Denver, CO
- Reiz JL, Darke AC. Steady-state pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. Can J Clin Pharmacol 2003;10(3):131
- Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999;161(5):1551–5
- Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50(6 Suppl 1):90–6
- Bemelmans BL, Kiemeney LA, Debruyne FM. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol 2000;37(6):709–13
- Hashimoto K, Ohnishi N, Esa A, Sugiyama T, Park Y, Kurita T. Clinical efficacy of oxybutynin on sensory urgency as compared with that on motor urgency. Urol Int 1999;62(1):12–6
- Tincello DG, Adams EJ, Sutherst JR, Richmond DH. Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. BJU Int 2000;85(4):416–20
- Staskin DR, Dmochowski RR. Future studies of overactive bladder: the need for standardization. Urology 2002;60 (5 Suppl 1):90–3